Addex gabab positive allosteric modulator program to receive additional chf2.7 million from indivior in extended substance use disorder research collaboration

Discovery c ollaboration on track to deliver clinical candidate s for ind enabling studies in 2024 ad hoc announcement pursuant to art. 53 lr geneva, switzerland, august 3 , 202 3 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its collaboration agreement with indivior plc (lon: indv) for the discovery of novel oral gamma-aminobutyric acid subtype b (gabab) positive allosteric modulator (pam) drug candidates for the treatment of substance use disorder has been extended until june 30, 2024.
ADXN Ratings Summary
ADXN Quant Ranking